• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection.系统评价:幽门螺杆菌感染的三线药敏指导治疗
Therap Adv Gastroenterol. 2016 Jul;9(4):437-48. doi: 10.1177/1756283X15621229. Epub 2015 Dec 16.
2
Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection.系统评价与荟萃分析:幽门螺杆菌感染的药敏指导治疗与经验性抗生素治疗
J Antimicrob Chemother. 2015 Sep;70(9):2447-55. doi: 10.1093/jac/dkv155. Epub 2015 Jun 14.
3
Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Infection: A Systematic Review and Meta-Analysis.易感性指导治疗与含铋四联疗法作为感染一线治疗的比较:一项系统评价和荟萃分析
Front Med (Lausanne). 2022 Mar 24;9:844915. doi: 10.3389/fmed.2022.844915. eCollection 2022.
4
Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?系统评价:目前的二线幽门螺杆菌治疗中,基于药敏的治疗方案能否实现可接受的治愈率?
Helicobacter. 2019 Jun;24(3):e12584. doi: 10.1111/hel.12584. Epub 2019 Apr 16.
5
Empirical vs. Susceptibility-Guided Treatment of Infection: A Systematic Review and Meta-Analysis.经验性治疗与药敏指导下的感染治疗:一项系统评价与Meta分析
Front Microbiol. 2022 Jun 14;13:913436. doi: 10.3389/fmicb.2022.913436. eCollection 2022.
6
Tailored therapy for eradication: A systematic review and meta-analysis.根除的个性化治疗:一项系统评价与荟萃分析。
Front Pharmacol. 2022 Sep 8;13:908202. doi: 10.3389/fphar.2022.908202. eCollection 2022.
7
Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication.系统评价和网络荟萃分析:二线幽门螺杆菌根除治疗的疗效比较。
J Gastroenterol Hepatol. 2019 Jan;34(1):59-67. doi: 10.1111/jgh.14462. Epub 2018 Oct 11.
8
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.基于强力霉素和阿莫西林的一周四联疗法在幽门螺杆菌感染的培养指导三线治疗方法中疗效显著。
Aliment Pharmacol Ther. 2004 Apr 1;19(7):789-95. doi: 10.1111/j.1365-2036.2004.01910.x.
9
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.韩国患者中基于培养的幽门螺杆菌根除定制疗法与传统二线挽救疗法疗效的比较:一项前瞻性单中心研究
Scand J Gastroenterol. 2016 Mar;51(3):270-6. doi: 10.3109/00365521.2015.1095352. Epub 2015 Oct 9.
10
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.幽门螺杆菌治疗失败后的经验性挽救治疗:一项针对500例患者的10年单中心研究。
Aliment Pharmacol Ther. 2008 Feb 15;27(4):346-54. doi: 10.1111/j.1365-2036.2007.03573.x. Epub 2007 Nov 12.

引用本文的文献

1
Two-dimension Tailor-made Therapy: A New Salvage Therapy After Multiple Eradication Failures for Infection.二维定制疗法:多次根除失败后针对感染的一种新的挽救疗法。
Gastro Hep Adv. 2022 Feb 3;1(2):210-222. doi: 10.1016/j.gastha.2021.11.006. eCollection 2022.
2
Drug-Resistant : Diagnosis and Evidence-Based Approach.耐药性:诊断与循证方法
Diagnostics (Basel). 2023 Sep 14;13(18):2944. doi: 10.3390/diagnostics13182944.
3
Current paradigms in the management of refractory Helicobacter pylori infection.难治性幽门螺杆菌感染的当前管理范式。
Indian J Gastroenterol. 2023 Dec;42(6):766-779. doi: 10.1007/s12664-023-01448-3. Epub 2023 Sep 22.
4
Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.基于药敏的序贯治疗与经验性治疗幽门螺杆菌感染的随机对照研究方案
Trials. 2023 Jun 19;24(1):413. doi: 10.1186/s13063-023-07457-z.
5
Third-line and rescue therapy for refractory infection: A systematic review.三线及挽救治疗难治性感染:系统评价。
World J Gastroenterol. 2023 Jan 14;29(2):390-409. doi: 10.3748/wjg.v29.i2.390.
6
Clinical Implications of Antibiotic Resistance in Italy: A Review of the Literature.意大利抗生素耐药性的临床影响:文献综述
Antibiotics (Basel). 2022 Oct 21;11(10):1452. doi: 10.3390/antibiotics11101452.
7
Empirical vs. Susceptibility-Guided Treatment of Infection: A Systematic Review and Meta-Analysis.经验性治疗与药敏指导下的感染治疗:一项系统评价与Meta分析
Front Microbiol. 2022 Jun 14;13:913436. doi: 10.3389/fmicb.2022.913436. eCollection 2022.
8
Clinical Relevance of Infection.感染的临床相关性
J Clin Med. 2021 Aug 6;10(16):3473. doi: 10.3390/jcm10163473.
9
Empirical or susceptibility-guided treatment for infection? A comprehensive review.感染的经验性治疗还是药敏指导治疗?一项全面综述。
Therap Adv Gastroenterol. 2020 Nov 12;13:1756284820968736. doi: 10.1177/1756284820968736. eCollection 2020.
10
Resistance patterns of refractory infection in a referral center in the Delaware Valley.特拉华谷转诊中心难治性感染的耐药模式。
GastroHep. 2020 Jan;2(1):6-12. doi: 10.1002/ygh2.382. Epub 2019 Dec 23.

本文引用的文献

1
Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection.系统评价与荟萃分析:幽门螺杆菌感染的药敏指导治疗与经验性抗生素治疗
J Antimicrob Chemother. 2015 Sep;70(9):2447-55. doi: 10.1093/jac/dkv155. Epub 2015 Jun 14.
2
Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.基于利福布汀的高剂量质子泵抑制剂和阿莫西林三联疗法作为幽门螺杆菌的挽救治疗方案。
Helicobacter. 2014 Dec;19(6):455-61. doi: 10.1111/hel.12147. Epub 2014 Sep 18.
3
Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.基于克拉霉素敏感性和胃酸分泌维持的个性化幽门螺杆菌根除治疗的疗效
Helicobacter. 2014 Aug;19(4):312-8. doi: 10.1111/hel.12128. Epub 2014 Apr 1.
4
Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.补救治疗,含铋剂四联方案,用于治疗对克拉霉素和左氧氟沙星耐药的幽门螺杆菌感染,在二线治疗失败后。
Dig Dis Sci. 2014 Feb;59(2):383-9. doi: 10.1007/s10620-013-2900-x. Epub 2013 Oct 15.
5
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.根据与克拉霉素耐药相关的 23S 核糖体 RNA 点突变根除幽门螺杆菌。
J Infect Dis. 2013 Oct 1;208(7):1123-30. doi: 10.1093/infdis/jit287. Epub 2013 Jun 24.
6
Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.基于培养的选择疗法用于治疗先前对幽门螺杆菌感染治疗无反应的患者。
Clin Gastroenterol Hepatol. 2013 May;11(5):507-10. doi: 10.1016/j.cgh.2012.12.007. Epub 2012 Dec 23.
7
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.基于基因型耐药指导的序贯治疗在难治性幽门螺杆菌感染三线治疗中的疗效:一项多中心临床试验。
J Antimicrob Chemother. 2013 Feb;68(2):450-6. doi: 10.1093/jac/dks407. Epub 2012 Oct 25.
8
Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.在澳大利亚西部使用新型四联疗法根除幽门螺杆菌。
Aliment Pharmacol Ther. 2012 Dec;36(11-12):1076-83. doi: 10.1111/apt.12089. Epub 2012 Oct 16.
9
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.根治幽门螺杆菌感染的治疗策略的疗效。
World J Gastroenterol. 2012 Sep 7;18(33):4542-8. doi: 10.3748/wjg.v18.i33.4542.
10
Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.非铋四联(联合)疗法:对克拉霉素敏感的幽门螺杆菌的经验性和针对性疗效与标准三联疗法相比,以及对克拉霉素耐药菌株的序贯疗法相比。
Helicobacter. 2012 Aug;17(4):269-76. doi: 10.1111/j.1523-5378.2012.00947.x. Epub 2012 Mar 30.

系统评价:幽门螺杆菌感染的三线药敏指导治疗

Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection.

作者信息

Puig Ignasi, López-Góngora Sheila, Calvet Xavier, Villoria Albert, Baylina Mireia, Sanchez-Delgado Jordi, Suarez David, García-Hernando Victor, Gisbert Javier P

机构信息

Digestive Diseases Unit, Althaia Xarxa Assistencial Universitaria de Manresa. Barcelona, Spain.

Internal Medicine Department, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain.

出版信息

Therap Adv Gastroenterol. 2016 Jul;9(4):437-48. doi: 10.1177/1756283X15621229. Epub 2015 Dec 16.

DOI:10.1177/1756283X15621229
PMID:27366212
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4913327/
Abstract

BACKGROUND

Susceptibility-guided therapies (SGTs) have been proposed as preferable to empirical rescue treatments after two treatment failures. The aim of this study was to perform a systematic review and meta-analysis evaluating the effectiveness and efficacy of SGT as third-line therapy.

METHODS

A systematic search was performed in multiple databases. Studies reporting cure rates of Helicobacter pylori with SGT in third-line therapy were selected. A qualitative analysis describing the current evidence and a pooled mean analysis summarizing the cure rates of SGT in third-line therapy was performed.

RESULTS

No randomized controlled trials or comparative studies were found. Four observational studies reported cure rates with SGT in third-line treatment, and three studies which mixed patients with second- and third-line treatment also reported cure rates with SGT. The majority of the studies included the patients when culture had been already obtained, and so the effectiveness of SGT and empirical therapy has never been compared. A pooled mean analysis including four observational studies (283 patients) showed intention-to-treat and per-protocol eradication rates with SGT of 72% (95% confidence interval 56-87%; I(2) : 92%) and 80% (95% confidence interval 71-90%; I(2) : 80%), respectively.

CONCLUSIONS

SGT may be an acceptable option as rescue treatment. However, cure rates are, at best, moderate and this approach has never been compared with a well-devised empirical therapy. The evidence in favor of SGT as rescue therapy is currently insufficient to recommend its use.

摘要

背景

在两次治疗失败后,药敏指导治疗(SGT)被认为比经验性挽救治疗更可取。本研究的目的是进行一项系统评价和荟萃分析,以评估SGT作为三线治疗的有效性和疗效。

方法

在多个数据库中进行系统检索。选择报告SGT在三线治疗中幽门螺杆菌治愈率的研究。进行了描述当前证据的定性分析和汇总SGT在三线治疗中治愈率的合并均值分析。

结果

未找到随机对照试验或比较研究。四项观察性研究报告了SGT在三线治疗中的治愈率,三项将二线和三线治疗患者混合的研究也报告了SGT的治愈率。大多数研究纳入了已经获得培养结果的患者,因此从未比较过SGT和经验性治疗的有效性。一项纳入四项观察性研究(283例患者)的合并均值分析显示,SGT的意向性治疗和符合方案根除率分别为72%(95%置信区间56-87%;I²:92%)和80%(95%置信区间71-90%;I²:80%)。

结论

SGT作为挽救治疗可能是一个可接受的选择。然而,治愈率充其量只是中等水平,并且这种方法从未与精心设计的经验性治疗进行过比较。支持SGT作为挽救治疗的证据目前不足以推荐其使用。